Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Plans Itvisma PA | OpenPay…
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy CS2026D0142D

    Itvisma (onasemnogene abeparvovec-brve) Medical Benefit Drug Policy

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy CS2026D0142D alerts

    Get alerted when Policy CS2026D0142D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit prior authorization and coverage of a single lifetime treatment with Itvisma for spinal muscular atrophy in eligible patients, subject to applicable state-specific exceptions.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyItvisma (onasemnogene abeparvovec-brve) Medical Benefit Drug Policy
    Policy CodePolicy CS2026D0142D
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing all listed medical-necessity criteria for Itvisma treatment.
    SourceLink
    POLICY UPDATE CHANGES

    The concomitant SMN-modifying therapy criterion was revised to remove language stating that current authorizations would be terminated upon Itvisma approval.

    Coverage criteria were revised to remove the requirement that current authorizations for concomitant SMN-modifying therapy be terminated upon Itvisma approval.

    The supporting References section was updated to reflect current information.

    1Maximum Itvisma treatment per lifetime
    ≥2 yearsMinimum patient age for coverage

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 or 3
    Required SMN2 gene copies
    45 daysMaximum authorization duration
    J3405Itvisma procedure code listed
    1Coverage criterion materially revised

    Coverage Criteria

    Initial Therapy

    Itvisma is covered for one treatment per lifetime when ALL of the following initial-therapy criteria are met:

    ALL of the following

      • ONE of

        • Homozygous gene deletion or mutation of the survival motor neuron 1 (SMN1) gene (e.g., homozygous deletion of exon 7 at locus 5q13).
        • Compound heterozygous mutation of the SMN1 gene (e.g., deletion of SMN1 exon 7 on allele 1 and mutation of SMN1 on allele 2).
    • Medical records (e.g., chart notes and laboratory values) confirm that the patient has 2 or 3 SMN2 gene copies.
    • Patient is at least 2 years of age.>= 2 years
    • Patient is not dependent on either of the following

      • Invasive ventilation or tracheostomy.
      • Non-invasive ventilation beyond use for naps and nighttime sleep.
    • Itvisma is prescribed by a neurologist with expertise in the treatment of SMA.
    • Patient is not receiving routine concomitant SMN-modifying therapy (e.g., Evrysdi [risdiplam] or Spinraza [nusinersen]); the patient's medical record will be reviewed.
    • Patient does not have an elevated anti-AAV9 antibody titer above 1:50.<= 1:50
    • Patient will receive prophylactic prednisolone or a glucocorticoid equivalent before and after Itvisma in accordance with FDA-approved Itvisma labeling.
    • Patient will receive Itvisma as a single-dose intrathecal injection in accordance with FDA-approved labeling.
    • Patient has never received gene therapy treatment for SMA in their lifetime, including Zolgensma (onasemnogene abeparvovec-xioi) or Itvisma.
    • Provider does not request a planned inpatient admission for the sole purpose of administering Itvisma.
    • Authorization is requested for no more than one treatment per lifetime and for no longer than 45 days from approval.<= 45 days from approval

    Itvisma is not proven or medically necessary for the treatment of spinal muscular atrophy (SMA) in patients younger than 2 years of age or for SMA without chromosome 5q mutations or deletions. Coverage is also not available when the patient does not meet the policy's other initial-therapy requirements.

    Itvisma is not proven or medically necessary for routine combination treatment of SMA with concomitant SMN-modifying therapy.

    Initial Itvisma Treatment

    Initial Itvisma Treatment

    Itvisma is covered for one treatment per lifetime when all of the following criteria are met:

    Initial Itvisma treatment: The patient has qualifying SMN1 genetics and 2 or 3 SMN2 copies, is at least 2 years old, meets the respiratory-support restrictions, is treated by a neurologist with expertise in SMA, has an anti-AAV9 antibody titer not above 1:50, will not receive routine concomitant SMN-modifying therapy, will receive FDA-label-concordant glucocorticoid prophylaxis and single-dose intrathecal administration, has no prior SMA gene therapy, and does not require a planned inpatient admission solely for administration.One treatment per lifetime; authorization ≤45 days

    Applicable Codes and Coding Parameters

    Applicable Procedure CodeHCPCS
    J3405Injection, onasemnogene abeparvovec-brve, per treatment.
    Applicable Diagnosis CodesICD-10
    G12.0Infantile spinal muscular atrophy, type I [Werdnig-Hoffmann].
    G12.1Other inherited spinal muscular atrophy.
    G12.25Progressive spinal muscle atrophy.
    G12.8Other SMAs and related syndromes.
    G12.9Spinal muscular atrophy, unspecified.
    Patient age
    Minimum qualifying ageAt least 2 years
    Coverage eligibilityPatient is ≥ 2 years of age
    Age exclusionPatients younger than 2 years are not eligible
    SMN2 gene copies
    Required SMN2 copy number2 or 3 copies
    Qualifying rangeTwo to three SMN2 gene copies
    Documentation

    Prior Authorization and Documentation

    Prior Authorization

    Initial Itvisma Authorization

    Prior authorization is required for Itvisma. Submit medical records supporting medical necessity, including the patient’s SMA diagnosis, qualifying genetic findings, clinical eligibility, treatment history, and planned administration details. Authorization is limited to one treatment per lifetime and no longer than 45 days from approval.

    • The request must be prescribed by a neurologist with expertise in treating SMA.
    • The patient must receive Itvisma as a single-dose intrathecal injection in accordance with FDA-approved labeling.
    • The patient must receive prophylactic prednisolone or a glucocorticoid equivalent before and after treatment according to FDA-approved labeling.
    Documentation Required

    Genetic Documentation Required

    Submit chart notes, laboratory values, or other medical records confirming a qualifying chromosome 5q genetic abnormality causing SMA.

    Spinal Muscular Atrophy

    Spinal muscular atrophy is a rare autosomal recessive neurodegenerative disorder caused primarily by biallelic SMN1 variants. Loss of SMN1 function leads to degeneration of spinal motor neurons, hypotonia, and progressive muscle weakness. The number of SMN2 gene copies is an important predictor of clinical phenotype.

    Lifetime Treatment Limit

    Itvisma quantity limit
    Quantity limitOne treatment per lifetime
    Lifetime limitOne Itvisma treatment
    Authorization requirementAuthorization will be issued for no more than one treatment per lifetime

    Administration Setting

    Billing Rule

    Administer Itvisma in the office

    Administer Itvisma as a single-dose intrathecal injection in accordance with FDA-approved labeling. A planned inpatient admission solely for administration is not covered.

    • Use the office setting for the administration.
    • The policy allows one treatment per lifetime.
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyItvisma (onasemnogene abeparvovec-brve) Medical Benefit Drug Policy
    Policy CodePolicy CS2026D0142D
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation establishing all listed medical-necessity criteria for Itvisma treatment.
    SourceLink
    On This Page
    Coverage CriteriaInitial Itvisma TreatmentApplicable Codes and Coding ParametersPrior Authorization and DocumentationSpinal Muscular AtrophyLifetime Treatment LimitAdministration Setting
    Medical records must confirm the patient has 2 or 3 SMN2 gene copies
    Anti-AAV9 antibody titer
    Maximum qualifying titerNot above 1:50
    Eligibility requirementThe patient must not have an elevated anti-AAV9 antibody titer above 1:50
    Exclusion thresholdTiters above 1:50 do not qualify
    Authorization duration
    Maximum authorization durationNo longer than 45 days from approval
    Authorization limit45 days from approval
    Policy requirementAuthorization will be issued for no longer than 45 days from approval
    • Homozygous SMN1 gene deletion or mutation, such as homozygous deletion of exon 7 at locus 5q13; or
    • Compound heterozygous SMN1 mutations, such as deletion of SMN1 exon 7 on one allele and an SMN1 mutation on the other allele.

    Unsupported block type: documentation

    Documentation Required

    HFMSE Quality Assessment

    For quality purposes, the provider must attest that the patient will receive Hammersmith Functional Motor Scale Expanded (HFMSE) assessments. This information does not affect the individual coverage determination.

    • Establish a baseline HFMSE functional assessment within the 2 weeks before Itvisma administration.
    • Assess the patient with HFMSE during subsequent office visits while the patient remains under the provider’s care.
    Documentation Required

    Medical-Record Review at Approval

    When Itvisma approval is considered, the patient’s medical record will be reviewed for routine concomitant SMN-modifying therapy, including Evrysdi (risdiplam) and Spinraza (nusinersen). Ensure the record clearly supports that routine concomitant therapy will not be continued with Itvisma.

    • The review reflects the revised requirement that the medical record be reviewed; current authorizations for SMN-modifying therapy are not stated as being automatically terminated upon Itvisma approval.
    Denial Risk

    Clinical and Authorization Exclusions

    Coverage may be denied when any required clinical or authorization condition is not met. Itvisma is not proven or medically necessary for SMA without qualifying chromosome 5q mutations or deletions, for patients younger than 2 years, or for routine combination treatment with concomitant SMN-modifying therapy.

    • The patient must have 2 or 3 SMN2 gene copies, supported by medical records.
    • The patient must be at least 2 years of age.
    • The patient must not depend on invasive ventilation or tracheostomy, or on non-invasive ventilation beyond naps and nighttime sleep.
    • The patient must not have an elevated anti-AAV9 antibody titer above 1:50.
    • The patient must not have received gene therapy for SMA, including Zolgensma (onasemnogene abeparvovec-xioi) or Itvisma, at any time in the patient’s lifetime.
    • Itvisma is limited to one treatment per lifetime.
    Denial Risk

    Inpatient-Only Administration Not Covered

    A planned inpatient admission solely for administration of Itvisma is not eligible for coverage. Do not request inpatient admission for the sole purpose of administering the treatment.

    • Itvisma must be administered as a single-dose intrathecal injection in accordance with FDA-approved labeling.